New coding guidance: 5 MACs set dates for new botulinum LCD, migraine treatments included

Why This Topic Matters

The policy affects whether botulinum toxin injection claims tied to chronic migraine and related headache care are payable under several MAC jurisdictions. Understanding the article helps practices align documentation and service selection with the new LCD and avoid denials when the policy takes effect.

Article Sections

1. Overview of the new LCD

   Introduces the new uniform local coverage determination and identifies the MACs adopting it. Summarizes the general clinical area addressed by the policy.

2. Coverage criteria and documentation themes

   Reviews the broad documentation and medical-necessity themes tied to chronic migraine coverage. Covers diagnostic framework, treatment history, and follow-up assessment concepts at a high level.

3. What is not covered

   Describes the categories of services and scenarios that the LCD excludes. Includes general noncoverage themes related to other procedures, certain headache conditions, mixed-use claims, and dose limits.

4. Resources

   Lists the MAC LCD reference resources and jurisdictions mentioned in the article.